Stockreport

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL

Cellectis S.A. - American Depositary Shares  (CLLS) 
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: cellectis.com/en/investors
PDF  ? Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ? Safety: in Phase 1 (n=40), lasme-cel was g [Read more]